DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Osterman M, Sandborn W, Colombel JF. et al.
Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for crohn`s disease.
Gastroenterology 2014;
146: 941-949
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.